Allison E. Sahr

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

Linda M. Rorick‐Kehn, Jeffrey M. Witkin, Michael A. Statnick et al. · Neuropharmacology · 2013 · 148 citations

Psychoactive Drug, Psychiatry, Functional Selectivity +7

A Model of Binge‐Like Eating Behavior in Mice That Does Not Require Food Deprivation or Stress

Traci A. Czyzyk, Allison E. Sahr, Michael A. Statnick · Obesity · 2010 · 82 citations

Activation of mesolimbic dopamine neurons during novel and daily limited access to palatable food is blocked by the opioid antagonist LY255582

Allison E. Sahr, Dana K. Sindelar, Jesline Alexander-Chacko et al. · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · 2008 · 48 citations

Food Intake, Experimental Pharmacology, Piperidine Series +25

Long‐Lasting Alterations of the Mesolimbic Dopamine System After Periadolescent Ethanol Drinking by Alcohol‐Preferring Rats

Allison E. Sahr, Richard J. Thielen, Lawrence Lumeng et al. · Alcoholism Clinical and Experimental Research · 2004 · 47 citations

Genetic ablation of myelin protein zero-like 3 in mice increases energy expenditure, improves glycemic control, and reduces hepatic lipid synthesis

Traci A. Czyzyk, Jessica L. Andrews, Tamer Coşkun et al. · American Journal of Physiology-Endocrinology and Metabolism · 2013 · 18 citations